Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring
The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for
Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc.
Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies
Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual
Key Concepts: While the current diagnostic strategies for PD-L1 checkpoint inhibitors identify some responders well, the majority of patients still need diagnostic approaches that better